Proteo Biotech AG, founded as a spin-off of the University of Kiel in 2000, researches, develops and markets nature identical compounds for biological and medical research as well as for use as pharmaceuticals. The Company’s focus is on the development of anti-inflammatory treatments for rare diseases with significant unmet needs. Proteo is engaged in the development of pharmaceuticals based on the body’s own tools and weapons to fight inflammatory diseases. The key personnel of Proteo has gained considerable expertise in basic, preclinical and clinical research on human inflammatory diseases over more than 25 years. For the development of its lead product Elafin Proteo has established a network of globally renowned research institutes, physicians and hospitals in Europe and the USA.
Proteo Biotech AG, located in Kiel, Germany, is a wholly-owned subsidiary of Proteo Inc., USA.